Showing results (101-110 of 175) with videos related to
Sort By:
Pageof 18
Gynecologic Oncology|March 31, 2000
Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group studyM Markman, J A Blessing, R D Alvarez, et al.Gynecologic Oncology|January 19, 2000
Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology groupR J Schilder, J A Blessing, M Morgan, et al.Seminars in Oncology|April 1, 1990
Gynecologic Oncology Group experience with ifosfamideG P Sutton, J A Blessing, G Photopulos, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 14, 2004
Evaluation of tamoxifen in persistent or recurrent nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group studyL R Bigler, J Tate Thigpen, J A Blessing, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1994
Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group studyJ T Thigpen, J A Blessing, H Ball, et al.American Journal of Clinical Oncology|August 24, 2000
Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group StudyD S Miller, J A Blessing, L C Kilgore, et al.American Journal of Obstetrics and Gynecology|March 1, 1993
Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group studyG P Sutton, J A Blessing, W P McGuire, et al.American Journal of Clinical Oncology|February 1, 1996
A phase II trial of merbarone (NSC 336628) in the treatment of recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group StudyK Y Look, J A Blessing, M D Adelson, et al.American Journal of Clinical Oncology|April 1, 1996
A phase II trial of didemnin B (NSC #335319) in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group StudyJ H Malfetano, J A Blessing, H D Homesley, et al.Gynecologic Oncology|December 22, 1999
Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology GroupD H Moore, J A Blessing, C Dunton, et al.Pageof 18